From Silent Clones to Myeloma: Unraveling the Genetic Clues Behind MGUS and Smoldering Myeloma
Abstract
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are distinct precursor conditions within the disease progression spectrum that can potentially lead to multiple myeloma (MM). This analysis elucidates the marked disparity in progression kinetics between these precursor states—with MGUS demonstrating an annual conversion rate of approximately 1% versus the substantially elevated 10-15% progression rate observed in SMM—thus emphasizing the critical necessity for precise risk stratification methodologies. The molecular pathogenesis underlying progression encompasses complex genetic and epigenetic perturbations, including chromosomal aberrations, somatic mutations, and dysregulation of epigenetic regulatory mechanisms such as DNA methylation patterns and histone modification profiles. The incorporation of molecular biomarkers, particularly recurrent chromosomal translocations and driver gene mutations, into prognostic algorithms has demonstrably enhanced the discriminatory capacity to identify high-risk patient subsets who may derive benefit from intensified surveillance protocols and preemptive therapeutic interventions. The translational integration of comprehensive genetic and genomic profiling into clinical decision-making paradigms for MGUS and SMM patients carries profound implications, facilitating individualized surveillance strategies and potentially enabling precision medicine approaches that may interrupt or slow down the advancement to symptomatic multiple myeloma.
References
Amodio, N., D’Aquila, P., Passarino, G., Tassone, P., & Bellizzi, D. (2017). Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation. Expert opinion on therapeutic targets, 21(1), 91-101. https://doi.org/10.1080/14728222.2016.1266339
Barwick, B. G., Gupta, V. A., Vertino, P. M., & Boise, L. H. (2019). Cell of origin and genetic alterations in the pathogenesis of multiple myeloma. Frontiers in immunology, 10, 1121. https://doi.org/10.3389/fimmu.2019.01121
Bolli, N., Genuardi, E., Ziccheddu, B., Martello, M., Oliva, S., & Terragna, C. (2020). Next-generation sequencing for clinical management of multiple myeloma: ready for prime time?. Frontiers in Oncology, 10, 189. https://doi.org/10.3390/cancers15051508
Botta, C., Mendicino, F., Martino, E. A., Vigna, E., Ronchetti, D., Correale, P., ... & Gentile, M. (2021). Mechanisms of immune evasion in multiple myeloma: open questions and therapeutic opportunities. Cancers, 13(13), 3213. https://doi.org/10.3390/cancers13133213
Brighton, T. A., Khot, A., Harrison, S. J., Ghez, D., Weiss, B. M., Kirsch, A., Magen, H., Gironella, M., Oriol, A., & Streetly, M. (2019). Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma. Clinical Cancer Research, 25(13), 3772–3775. https://doi.org/10.1158/1078-0432.ccr-18-3470
Bustin, S. A., & Jellinger, K. A. (2023). Advances in molecular medicine: unravelling disease complexity and pioneering precision healthcare. International Journal of Molecular Sciences, 24(18), 14168. https://doi.org/10.3390/ijms241814168
Bustoros, M., Sklavenitis-Pistofidis, R., Park, J., Redd, R., Zhitomirsky, B., Dunford, A. J., Salem, K., Tai, Y.-T., Anand, S., & Mouhieddine, T. H. (2020). Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression. Journal of Clinical Oncology, 38(21), 2380–2389. https://doi.org/10.1200/jco.20.00437
Cowan, A., Ferrari, F., Freeman, S. S., Redd, R., El-Khoury, H., Perry, J., Patel, V., Kaur, P., Barr, H., & Lee, D. J. (2023). Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. The Lancet Haematology, 10(3), e203–e212. https://doi.org/10.1016/s2352-3026(22)00386-6
de Daniel, A., Rodríguez‐Lobato, L. G., Tovar, N., Cibeira, M. T., Moreno, D. F., Oliver‐Caldés, A., Isola, I., Lozano, E., Bladé, J., & Rosiñol, L. (2024). The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma. HemaSphere, 8(5), e76. https://doi.org/10.1016/s2352-3026(22)00386-6
Desai, R. H., Zandvakili, N., & Bohlander, S. K. (2022). Dissecting the genetic and non-genetic heterogeneity of acute myeloid leukemia using next-generation sequencing and in vivo models. Cancers, 14(9), 2182. https://doi.org/10.3390/cancers14092182
Desantis, V., Savino, F. D., Scaringella, A., Potenza, M. A., Nacci, C., Frassanito, M. A., ... & Montagnani, M. (2022). The leading role of the immune microenvironment in multiple myeloma: A new target with a great prognostic and clinical value. Journal of clinical medicine, 11(9), 2513. https://doi.org/10.3390/jcm11092513
Dhodapkar, M. V. (2016). MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood, The Journal of the American Society of Hematology, 128(23), 2599-2606. https://doi.org/10.1182/blood-2016-09-692954
Dutta, A. K., Alberge, J. B., Sklavenitis-Pistofidis, R., Lightbody, E. D., Getz, G., & Ghobrial, I. M. (2022). Single-cell profiling of tumour evolution in multiple myeloma—opportunities for precision medicine. Nature Reviews Clinical Oncology, 19(4), 223-236. https://doi.org/10.1038/s41571-021-00593-y
Ferla, V., Farina, F., Perini, T., Marcatti, M., & Ciceri, F. (2024). Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions. Pharmaceuticals, 17(7), 901. https://doi.org/10.3390/ph17070901
Ferla, V., Farina, F., Perini, T., Marcatti, M., & Ciceri, F. (2024). Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions. Pharmaceuticals, 17(7), 901. https://doi.org/10.3390/ph17070901
Fernandez de Larrea, C., Isola, I., Pereira, A., Cibeira, M. T., Magnano, L., Tovar, N., Rodríguez-Lobato, L.-G., Calvo, X., Aróstegui, J. I., & Díaz, T. (2018). Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. Leukemia, 32(6), 1427–1434. https://www.nature.com/articles/s41375-018-0013-4
Firdaus, Z., & Li, X. (2024). Unraveling the genetic landscape of neurological disorders: insights into pathogenesis, techniques for variant identification, and therapeutic approaches. International journal of molecular sciences, 25(4), 2320. https://doi.org/10.3390/ijms25042320
Ho, M., Patel, A., Goh, C. Y., Moscvin, M., Zhang, L., & Bianchi, G. (2020). Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Leukemia, 34(12), 3111-3125. https://doi.org/10.1038/s41375-020-01051-x
Jeremias, G., Gonçalves, F. J., Pereira, J. L., & Asselman, J. (2020). Prospects for incorporation of epigenetic biomarkers in human health and environmental risk assessment of chemicals. Biological Reviews, 95(3), 822-846. https://doi.org/10.1111/brv.12589
Kouroukli, O., Symeonidis, A., Foukas, P., Maragkou, M. K., & Kourea, E. P. (2022). Bone marrow immune microenvironment in myelodysplastic syndromes. Cancers, 14(22), 5656. https://doi.org/10.3390/cancers14225656
Kumar, K. R., Cowley, M. J., & Davis, R. L. (2024, October). Next-generation sequencing and emerging technologies. In Seminars in thrombosis and hemostasis (Vol. 50, No. 07, pp. 1026-1038). Thieme Medical Publishers. https://doi.org/10.1055/s-0044-1786397
Lakshman, A., Rajkumar, S. V., Buadi, F. K., Binder, M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Dingli, D., Fonder, A. L., & Hayman, S. R. (2018). Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal, 8(6), 59. https://doi.org/10.1038/s41408-018-0077-4
Lehmann, J., de Ligt, K. M., Tipelius, S., Giesinger, J. M., Sztankay, M., Voigt, S., ... & Holzner, B. (2023). Adherence to patient-reported symptom monitoring and subsequent clinical interventions for patients with multiple myeloma in outpatient care: longitudinal observational study. Journal of Medical Internet Research, 25, e46017. https://doi.org/10.2196/46017
Lobato-Delgado, B., Priego-Torres, B., & Sanchez-Morillo, D. (2022). Combining molecular, imaging, and clinical data analysis for predicting cancer prognosis. Cancers, 14(13), 3215. https://doi.org/10.3390/cancers14133215
Lonial, S., Jacobus, S., Fonseca, R., Weiss, M., Kumar, S., Orlowski, R. Z., Kaufman, J. L., Yacoub, A. M., Buadi, F. K., & O’Brien, T. (2020). Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. Journal of Clinical Oncology, 38(11), 1126–1137. https://doi.org/10.1200/jco.19.01740
Manasanch, E. E., Han, G., Mathur, R., Qing, Y., Zhang, Z., Lee, H., Weber, D. M., Amini, B., Berkova, Z., & Eterovic, K. (2019). A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Advances, 3(15), 2400–2408. https://doi.org/10.1182/bloodadvances.2019000300
Mateos, M.-V., Kumar, S., Dimopoulos, M. A., González-Calle, V., Kastritis, E., Hajek, R., De Larrea, C. F., Morgan, G. J., Merlini, G., & Goldschmidt, H. (2020). International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer Journal, 10(10), 102. https://doi.org/10.1038/s41408-020-00366-3
Nadeem, O., Redd, R., Stampleman, L. V, Matous, J. V, Yee, A. J., Zonder, J. A., Kin, A., Rosenblatt, J., Bustoros, M., & Prescott, J. (2019). A phase II study of daratumumab in patients with high-risk MGUS and low-risk smoldering multiple myeloma: first report of efficacy and safety. Blood, 134, 1898. http://dx.doi.org/10.1182/blood-2019-129103
Najafi, M., Majidpoor, J., Toolee, H., & Mortezaee, K. (2021). The current knowledge concerning solid cancer and therapy. Journal of biochemical and molecular toxicology, 35(11), e22900. https://doi.org/10.1002/jbt.22900
Peneder, P., Stütz, A. M., Surdez, D., Krumbholz, M., Semper, S., Chicard, M., ... & Tomazou, E. M. (2021). Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. Nature communications, 12(1), 3230. https://doi.org/10.1038/s41467-021-23445-w
Pérez-Escurza, O., Flores-Montero, J., Óskarsson, J. Þ., Sanoja-Flores, L., Del Pozo, J., Lecrevisse, Q., Martín, S., Reed, E. R., Hákonardóttir, G. K., & Harding, S. (2023). Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study. Blood Cancer Journal, 13(1), 182. https://doi.org/10.1038/s41408-023-00944-1
Robinson, M. H., Villa, N. Y., Jaye, D. L., Nooka, A. K., Duffy, A., McCachren, S. S., Manalo, J., Switchenko, J. M., Barnes, S., & Potdar, S. (2023). Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy. The Journal of Clinical Investigation, 133(15). https://doi.org/10.1172/JCI167629
Rodriguez-Otero, P., Paiva, B., & San-Miguel, J. F. (2021). Roadmap to cure multiple myeloma. Cancer treatment reviews, 100, 102284. https://doi.org/10.1016/j.ctrv.2021.102284
Sharma, A., Heuck, C. J., Fazzari, M. J., Mehta, J., Singhal, S., Greally, J. M., & Verma, A. (2010). DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2(6), 654-669. https://doi.org/10.1002/wsbm.89
Singh, S. R., Bhaskar, R., Ghosh, S., Yarlagadda, B., Singh, K. K., Verma, P., ... & Avtanski, D. (2025). Exploring the Genetic Orchestra of Cancer: The Interplay Between Oncogenes and Tumor-Suppressor Genes. Cancers, 17(7), 1082. https://doi.org/10.3390/cancers17071082
Stoffel, E. M., Brand, R. E., & Goggins, M. (2023). Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology, 164(5), 752-765. https://doi.org/10.1053/j.gastro.2023.02.012
Valkenburg, K. C., De Groot, A. E., & Pienta, K. J. (2018). Targeting the tumour stroma to improve cancer therapy. Nature reviews Clinical oncology, 15(6), 366-381. https://doi.org/10.1038/s41571-018-0007-1
van Nieuwenhuijzen, N., Spaan, I., Raymakers, R., & Peperzak, V. (2018). From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells. Cancer research, 78(10), 2449-2456. https://doi.org/10.1158/0008-5472.can-17-3115
Vasudevan, A., Schukken, K. M., Sausville, E. L., Girish, V., Adebambo, O. A., & Sheltzer, J. M. (2021). Aneuploidy as a promoter and suppressor of malignant growth. Nature Reviews Cancer, 21(2), 89-103. https://doi.org/10.1038/s41568-020-00321-1
Verma, M., Seminara, D., Arena, F. J., John, C., Iwamoto, K., & Hartmuller, V. (2006). Genetic and epigenetic biomarkers in cancer: improving diagnosis, risk assessment, and disease stratification. Molecular diagnosis & therapy, 10, 1-15. https://doi.org/10.1007/bf03256438
Wang, J., Zheng, Y., Tu, C., Zhang, H., Vanderkerken, K., Menu, E., & Liu, J. (2020). Identification of the immune checkpoint signature of multiple myeloma using mass cytometry‐based single‐cell analysis. Clinical & Translational Immunology, 9(5), e1132. https://doi.org/10.1002/cti2.1132
Wong, N. D., Budoff, M. J., Ferdinand, K., Graham, I. M., Michos, E. D., Reddy, T., ... & Toth, P. P. (2022). Atherosclerotic cardiovascular disease risk assessment: an American Society for Preventive Cardiology clinical practice statement. American Journal of Preventive Cardiology, 10, 100335. https://doi.org/10.1016/j.ajpc.2022.100335
Zavidij, O., Haradhvala, N. J., Mouhieddine, T. H., Sklavenitis-Pistofidis, R., Cai, S., Reidy, M., Rahmat, M., Flaifel, A., Ferland, B., & Su, N. K. (2020). Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nature Cancer, 1(5), 493–506. https://doi.org/10.1038/s43018-020-0053-3
Zuern, K., Hielscher, T., Werly, A., Breitkreutz, I., Sauer, S., Raab, M. S., Müller-Tidow, C., Goldschmidt, H., & Mai, E. K. (2024). Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance. Blood Cancer Journal, 14(1), 148. http://dx.doi.org/10.1038/s41408-024-01126-3
Copyright (c) 2025 Journal La Medihealtico
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
